drugset / Trial / NCT02924753
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Phase 1
Unknown
20 enrolled
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study for patients who have been previously treated for B-ALL. The purpose of this study is to determine the safety and feasibility of CART-19 cells to the patients with relapsed and refractory CD19+ B-ALL.
Timeline
- Start
- 2016-07-18
- Primary completion
- 2019-07
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-19 cells | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | 0.8 g | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1 g | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |